Education

: Speaker List

Speaker View

Below is a listing of all sessions the speaker is scheduled to present.

Manon Cox

President & CEO

Protein Sciences Corporation

Speaker Bio

Manon Cox is currently President and CEO at Protein Sciences Corporation. Since 2006, she also serves on the Scientific Advisory Board of Pall BioPharmaceuticals. She joined Protein Sciences in 1998 as Director of Business Development. Previously she was with Gist-brocades, a large Dutch company specialized in fermentation, where she held various management positions most recently in New Business Development, and before that in Production and Research and Development. Prior to joining Gist-brocades she worked as a Molecular Biologist on the development of a PCR screening test for cervical cancer at the University of Amsterdam. She holds a Doctorate in Virology from the University of Wageningen; received her MBA with distinction from the University of Nijenrode and the University of Rochester, NY and holds a Doctorandus degree in Molecular Biology, Genetics and Biochemistry from the University of Nijmegen, The Netherlands

Have a Question?

You can pose a question to the speaker by clicking on the " Suggest a Question

" icon at the end of the session title. Appropriate questions will be answered during the session as time permits (not all questions will be answered).

Wednesday, March 30, 2011

Conference Program

Pandemic Preparedness and the Manufacturing of an Emergency Vaccine: What Role can Single Use Systems Play?
Room: 1E15 ~ 2:00 pm - 3:30 pm (Wednesday, March 30, 2011)

The panel will approach the manufacturing of emergency vaccines from three angles followed by discussion with the audience to identify the most suitable, and economic solution for various scenarios.

The baculovirus production technology can support safe and expeditious vaccine production and provides an attractive alternative to the current egg-based influenza vaccine (TIV) manufacturing process. Protein Sciences Corporation was initially awarded a $34.5 million contract in June 2009 for an 18 month period from the U.S. Department of Health and Human Services to further develop this technology for the production of recombinant influenza vaccines for pandemic preparedness with the contract recently extended for another two year period.

The manufacturing process for FluBlok/PanBlok, a recombinant protein based influenza vaccine including the combination of single- and multi-use equipment in the current process will be described.

Possible scenarios for establishing surge capacity range from warm base manufacturing facilities (ready to go when they need to), to facilities used for the production of other products that can be rapidly deployed when needed through a hybrid approach, to fully disposable factories. The panel will evaluate advantages, and disadvantages of each scenario from a financial, regulatory, and engineering perspective.

Speaker:

Daniella Kranjac - Enterprise Project Leader, GE Healthcare Lifesciences

Kim Nelson - Director, Strategic Consulting, CRB Consulting Engineers

Moderator:

Manon Cox - President & CEO, Protein Sciences Corporation